Standing Order
AstraZeneca PLC

Dashboard

AstraZeneca PLC

AZNNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$253B
Price$163.3352w $68.72 – $209.48
Conviction4/ 5
Revenue (TTM)$61.4B
Revenue growth YoY+8.6%
P/E (trailing)24.2
Gross margin81.9%
Operating margin22.8%
Net margin17.0%
52w price change+123.7%
Next earningsNov 5, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Sep 23
    RegulatorySEC

    Trixeo approved in EU for asthma per 6-K filing.

  • Sep 21
    RegulatorySEC

    ENHERTU recommended for approval in EU for early breast cancer

  • Sep 21
    RegulatorySEC

    Klygefa recommended for EU approval by CHMP

  • Sep 18
    Ownership changeSEC

    6-K reports director/PDMR shareholding notification for AstraZeneca.

  • Sep 15
    Ownership changeSEC

    AstraZeneca 6-K reports director/PDMR shareholding notification.

  • Sep 15
    Ownership changeSEC

    6-K reports director/PDMR shareholding notification.

  • Sep 14
    Trial readoutSEC

    6-K filing provides update on SERENA-4 Phase III trial.

  • Sep 11
    Ownership changeSEC

    Form 4 insider ownership filing by AstraZeneca PLC.

  • Sep 8
    RegulatorySEC

    6-K reports US approval of ETCAMAH for HR+ breast cancer

  • Sep 8
    Trial readoutSEC

    6-K reports Imfinzi + Imdelltra improved OS in small cell lung cancer trial

  • Sep 1
    Securities offeringSEC

    AstraZeneca 6-K reports admission of further securities to trading.

  • Sep 1
    Securities offeringSEC

    6-K reports admission to trading for EUR2.55 billion bond offering.

  • Sep 1
    DealSEC

    AstraZeneca completes agreement for ZEGFROVY (6-K).

  • Sep 1
    Trial readoutSEC

    6-K reports TAGRISSO + ORPATHYS improved PFS in 1L EGFRm lung cancer.

  • Sep 1
    OtherSEC

    6-K filing reports total voting rights.

  • Sep 1
    LeadershipSEC

    AstraZeneca PLC reports a change to its board of directors in a 6-K filing.

  • Sep 1
    RegulatorySEC

    ENHERTU approved in EU for 1L HER2-positive metastatic breast cancer

  • Aug 27
    Trial readoutSEC

    Tezspire crossing trial met primary endpoints per 6-K filing.

  • Aug 25
    Securities offeringSEC

    AstraZeneca prices EUR2.55 billion bond offering.

  • Aug 19
    Ownership changeSEC

    6-K reports director/PDMR shareholding notification.

Not financial advice — research and opinion only. Disclosures